Startup BIOLIFE4D has filed a $50 million initial public offering with the Securities and Exchange Commission (SEC) under Regulation A+ rules for their project of 3D Bioprinting a Real Heart for transplants. Curerntly seeking investors, BIOLIFE4D plans to use recent breakthroughs in 3D printing, regenerative medicine, stem cell biology and computing techniques to create patient-specific replacement hearts from the patient’s own cells, eliminating both long waiting lists and risks of rejection.

 

Source: https://biolife4d.com/about/